Pentixapharm Holding AG (VIE:PTPN)

Austria · Delayed Price · Currency is EUR

2.055

-0.065 (-3.07%)

At close: Mar 2, 2026

Market Cap	51.55M
Revenue (ttm)	1.52M
Net Income (ttm)	-26.50M
Shares Out	n/a
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	676
Open	2.090
Previous Close	2.120
Day's Range	2.055 - 2.090
52-Week Range	1.330 - 3.550
Beta	n/a
RSI	53.62
Earnings Date	Apr 15, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2019

Employees 64

Stock Exchange Vienna Stock Exchange

Ticker Symbol PTPN

Full Company Profile

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.

Financial Statements

News

There is no news available yet.